Apex Labs, 1040 West Georgia Street, Vancouver, BC (2025)

11/25/2025

The numbers tell a story:
📊 322 million people globally live with depression 📊 280 million suffer from PTSD
📊 40-60% effectiveness rate for standard antidepressants
📊 Nearly 50% report unwanted side effects

Meanwhile, emerging clinical data on investigational psilocybin therapy has shown promising results in early trials—though larger studies are needed.

The gap between current options and what researchers are exploring has never been clearer.
At Apex Labs, we’re contributing to that exploration through rigorous Phase 2b trials in Canada and Israel, with plans for Phase 3 studies and regulatory submissions.
Because millions of people deserve researchers who won’t stop looking for better options.

Learn more at ApexLabs.com

11/20/2025

“Psychedelic-assisted therapy is the only reason I can be a present mother, wife and value to society. Psychedelic therapy is the only reason I am alive.”

This is —Canadian Armed Forces veteran, artillery gunner in Afghanistan, and mental health advocate.
After a decade of standard PTSD care, she was told she’d need electroshock therapy before accessing psilocybin treatment through Canada’s Special Access Program. She refused and advocated for a different path.
In October 2023, Kelsi became the first veteran to receive Apex Labs’ APEX-90 investigational therapy through Health Canada’s Special Access Program for compassionate use.
Her experience highlights why we’re conducting clinical trials. Veterans die by su***de at rates 50-250% higher than the general population. They deserve to have researchers exploring every scientifically-valid option.

As a Veteran-founded company, Apex Labs has built its clinical development strategy around serving those who served. Both APEX-52 (microdose) and APEX-90 (macrodose) are being studied in clinical trials, with Veteran patients participating in both clinical and early access settings in Canada.
We’re working to generate the evidence that could make these treatments available to everyone who needs them.

Read More: sencanada.ca

11/18/2025

Yale’s Program for Psychedelic Science recently shared perspectives on where the research stands.
Dr. Benjamin Kelmendi, co-director of the program, noted “compelling evidence” emerging in treatment-resistant depression and major depressive disorder research. He emphasized that results in PTSD research with veteran populations have been encouraging, though he noted larger trials are still ongoing.

Yale’s message was clear: this research shows promise, but it needs to advance through proper clinical trials with validated protocols, trained professionals, and appropriate safeguards before any approvals.

That’s exactly the approach Apex Labs has taken from day one. Rigorous science. Veteran-focused clinical trials. Full regulatory alignment.
We’re in Phase 2b trials now, building the evidence base that regulatory bodies need to evaluate these potential treatments.

Read more at news.yale.edu

11/14/2025

Why is Apex Labs developing two different psilocybin formulations?
Because depression and PTSD aren’t one-size-fits-all conditions.

APEX-52 (Microdose): Being studied for moderate depression and PTSD in a take-home format. Designed for patients who may benefit from lower-dose, ongoing support.
APEX-90 (Macrodose): Being studied for severe, treatment-resistant cases in a controlled clinical setting with assisted psychotherapy. For patients who haven’t responded to conventional treatments.

Both are currently in Phase 2b trials, with Veteran patients participating in clinical and early access settings in Canada.
Our approach: match the intervention to the severity and needs of the patient. Not everyone needs the same level of care, and research design should reflect that.
This is what patient-driven pharmaceutical development looks like.

Learn more at ApexLabs.com

11/10/2025

Nature just revealed one of its most fascinating secrets: magic mushrooms evolved the ability to produce psilocybin twice—completely independently.
Two different mushroom species, separated by millions of years, developed entirely different biochemical pathways to create the exact same compound. Scientists are still investigating why.

What matters for medicine: this discovery provides new enzyme tools that could improve how psilocybin-based treatments are produced for research and clinical trials.
At Apex Labs, we’re developing two distinct investigational psilocybin-based therapies currently in clinical trials: • APEX-52 (Microdose): Being studied for moderate depression and PTSD • APEX-90 (Macrodose): Being studied for severe cases with in-clinic support
Both have been used with Veterans in clinical and early access settings in Canada, with promising preliminary results.

Nature invented psilocybin twice. Now researchers like us are working to understand if it can become a safe, accessible treatment option through proper clinical trials and regulatory approval.

Read more at sciencedaily.com

11/06/2025

A significant milestone in Australia: Medibank, the country’s largest private health insurer, is now reimbursing psilocybin-assisted therapy for treatment-resistant depression in a pilot program. That’s 4.2 million customers with potential access.
This pilot represents growing institutional confidence in psychedelic medicine when delivered in controlled clinical settings.
While this is Australian-specific, it signals a broader shift toward exploring how evidence-based psychedelic treatments could become more accessible globally.

At Apex Labs, we’re working toward that future through Phase 2b clinical trials in Canada and Israel—building the evidence base that could eventually support similar access programs.
Because 322 million people worldwide living with depression deserve to see innovation in mental health care.

Read More at investingnews.com

11/03/2025

New research from Penn Medicine is revealing something interesting about brain circuits and chronic pain.
In animal studies, researchers found that psilocybin targeted specific circuits in the anterior cingulate cortex—the region that processes both pain and emotions. The compound appeared to work like a “dimmer switch” on these signals, according to Dr. Joseph Cichon.
The research showed benefits lasting up to two weeks in the study, and researchers noted psilocybin is non-addictive, unlike opioids.

This is the kind of emerging science that informs our work at Apex Labs as we advance psilocybin-based therapies through rigorous clinical trials.
We’re focused on developing non-addictive approaches for those who need alternatives to current options.

Read More at sciencedaily.com

10/29/2025

Meet Dr. Mark Johnston, Apex Labs’ Chief Medical Officer.

For over two decades, he’s been running a private network of mental health clinics focused exclusively on veterans with PTSD and depression.
He’s seen what traditional treatments can’t deliver. He’s watched veterans cycle through ineffective medications and therapies that barely touch their trauma. As principal investigator on 25+ central nervous system clinical trials, he knows what rigorous research looks like.
Now he’s leading the clinical development of APEX-52 and APEX-90 – the dual psilocybin therapies designed specifically for the veteran community he’s spent his career serving.
Dr. Johnston didn’t just join Apex Labs for another clinical trial. He joined because after 20 years of watching veterans struggle with inadequate treatments, he finally found therapies that could actually help them heal.

When a physician stakes two decades of veteran care on breakthrough therapy, you know something extraordinary is happening.

10/27/2025

Why we built two different psilocybin treatments: accessibility means having real options.

At Apex Labs, we recognized something the industry was missing: not everyone with PTSD and depression needs the same level of intervention. That’s why we developed the first dual-drug approach in psychedelic medicine.

APEX-52: Take-home microdose treatment for moderate depression and PTSD. You dose yourself at home, on your schedule, with physician oversight.

APEX-90: In-clinic macrodose with assisted psychotherapy for severe cases. Full support, trained therapists, comprehensive care for those who need intensive treatment.

Both are patent-pending. Both achieved zero adverse events in veteran trials. Both represent something revolutionary: psilocybin therapy that adapts to your life, not the other way around.
We didn’t just make another psychedelic drug. We made the future of personalized mental health care.

Learn more at ApexLabs.com

10/23/2025

COMPASS just proved psilocybin works in Phase 3. FDA approval could be 18 months away.

The milestone everyone was waiting for just happened. COMPASS Pathways’ Phase 3 results showed their synthetic psilocybin significantly outperformed placebo for treatment-resistant depression - the first Phase 3 success for any classic psychedelic.

While investors initially reacted poorly (stock dropped 36%), the bigger picture is revolutionary: this proves psilocybin therapy works at the highest level of clinical evidence. COMPASS is now preparing their FDA submission for late 2026-2027, with approval potentially following within a year.

This isn’t speculation anymore. The first FDA-approved psilocybin therapy has a clear timeline, and we’re closer than ever to prescription psychedelic medicine becoming reality.

10/20/2025

While competitors chase single-dose clinic models, Apex Labs pioneered the comprehensive approach the market actually needs:

✓ World’s largest take-home psilocybin trial (294 patients)
✓ Revolutionary dual-drug strategy addressing full treatment spectrum
✓ First-mover advantages in accessible delivery models
✓ Veteran-focused differentiation with government recognition
✓ Patent-pending formulations with cost-effective manufacturing

The Canadian Senate specifically highlighted Apex’s program in their veteran access report. Media coverage spans Psychiatric Times to Clinical Trials Arena. Industry recognition positions Apex as the leader in making psychedelic medicine accessible rather than exclusive.

Learn more at ApexLabs.com

10/16/2025

294 patients taking psychedelic therapy home. We’re not just part of history – we’re writing it.

While other companies talk about the future of psychedelic medicine, at Apex Labs we’re focused on creating it:

✅ World’s largest take-home psilocybin trial (294 patients approved by Health Canada)
✅ First company to achieve legal medical psilocybin outside clinical trials in Canadian history
✅ First veteran dosed through our Early Access Program in 2023
✅ Patent-pending capsule technology improving bioavailability and stability
✅ FDA IND filed for driving safety studies at Yale School of Medicine

This isn’t just research – it’s real veterans getting real treatment right now. Canadian Armed Forces and RCMP veterans are accessing APEX therapies through Health Canada’s Special Access Program while we complete the largest accessibility studies ever conducted.

We don’t just study psilocybin therapy. We deliver it. Learn more at ApexLabs.com

Apex Labs

11/25/2025

11/20/2025

11/18/2025

11/14/2025

11/10/2025

11/06/2025

11/03/2025

10/29/2025

10/27/2025

10/23/2025

10/20/2025

10/16/2025

Address

Website

Alerts

Shortcuts

Share

Category